Citations

Clear

8 citation(s) found for "Wilson, Kathleen".

Costs of colorectal cancer screening with colonoscopy, including post-endoscopy events, among adults with Medicaid insurance
Fisher, Deborah A. , Princic, Nicole , Miller‐Wilson, Lesley‐Ann , Wilson, Kathleen , Limburg, Paul, Princic, Nicole , Limburg, Paul J.

Mayo Clinic

Current Medical Research and Opinion | March 4, 2022 | Volume: 38 | Issue: 5 | Pages: 793-801

10.1080/03007995.2022.2049163 | PMID 35243953 Get It

Healthcare costs of colorectal cancer screening and events following colonoscopy among commercially insured average-risk adults in the United States
Fisher, Deborah A. , Princic, Nicole , Miller‐Wilson, Lesley‐Ann , Wilson, Kathleen , Limburg, Paul, Princic, Nicole , Limburg, Paul J.

Mayo Clinic

Current Medical Research and Opinion | December 17, 2021 | Volume: 38 | Issue: 3 | Pages: 427-434

10.1080/03007995.2021.2015157 | PMID 34918589 Get It

Out-of-Pocket Costs for Colonoscopy After Noninvasive Colorectal Cancer Screening Among US Adults With Commercial and Medicare Insurance
Miller‐Wilson, Lesley‐Ann , Wilson, Kathleen , Limburg, Paul, Fendrick, A. Mark , Princic, Nicole , Limburg, Paul J.

Mayo Clinic

JAMA Network Open | December 2, 2021 | Volume: 4 | Issue: 12 | Pages: e2136798

10.1001/jamanetworkopen.2021.36798 | PMID 34854909 Get It

Utilization of a Colorectal Cancer Screening Test Among Individuals With Average Risk
Fisher, Deborah A. , Miller‐Wilson, Lesley‐Ann , Wilson, Kathleen , Limburg, Paul, Princic, Nicole , Fendrick, A. Mark , Limburg, Paul J.

Mayo Clinic

JAMA Network Open | September 2, 2021 | Volume: 4 | Issue: 9 | Pages: e2122269

10.1001/jamanetworkopen.2021.22269 | PMID 34473259 Get It

HER-2 Fluorescence In Situ Hybridization: Results From the Survey Program of the College of American Pathologists
Persons, Diane L., Tubbs, Raymond R., Cooley, Linda D. , Dewald, Gordon W., Dowling, Patricia K., Du, Emma, Mascarello, James T., Rao, Kathleen W., Wolff, Daynna J., Habegger-Vance, Gail, Wilson, Kathleen S.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 130 | Issue: 3 | Pages: 325-331

10.5858/2006-130-325-hfishr | PMID 16519559 Get It

Abstract Context. —Fluorescence in situ hybridization (FISH) is a common method used to determine HER-2 status in breast cancer. Limited information is available concerning reproducibility of FISH in determining HER-2 gene amplification. Objective. —To present proficiency testing results of FISH for HER-2 conducted by the Cytogenetics Resource Committee of the College of American Pathologists/American College of Medical Genetics. Design. —During the past 5 years, unstained sections from 9 invasive breast carcinomas were used for HER-2 FISH proficiency testing, allowing for comparison of FISH results among a large number of laboratories. Additional data were collected using an educational (ungraded) challenge and supplemental questions in the surveys. Results. —The number of laboratories participating in HER-2 FISH proficiency testing has increased steadily during the past 5 years (from 35 in 2000 to 139 in 2004). Reproducibility of test results among laboratories was excellent for breast tumors with low copy number (no HER-2 amplification) and for breast tumors with high copy number ( HER-2 amplification). However, there was considerable variation in interpretation of results for a tumor with low-level HER-2 amplification that was tested on 2 separate occasions. Responses to supplemental questions indicated that there was a need for consensus on the use of a separate equivocal/borderline interpretative category and the need for standardization of cutoff values used to define interpretative categories. Conclusions. —The College of American Pathologists proficiency survey programs provide useful information concerning the reproducibility of clinical testing for HER-2 by FISH and reflect clinical interpretation of HER-2 FISH analyses from laboratories across the country.
S0577 Healthcare Costs of Colonoscopy With and Without Complications Among Patients at Average Risk for Colorectal Cancer in the United States (US)
Fisher, Deborah A. , Miller‐Wilson, Lesley‐Ann , Wilson, Kathleen , Fendrick, Mark, Princic, Nicole , DeYoung, Kathryn, Limburg, Paul J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S259-S259

10.14309/01.ajg.0000704356.04032.d9 Get It

S0300 Real World Analysis of Adherence to Fecal Immunochemical Test and Fecal Occult Blood Test Among Patients at Average Risk for Colorectal Cancer
Fisher, Deborah A. , Miller‐Wilson, Lesley‐Ann , Wilson, Kathleen , Princic, Nicole , DeYoung, Kathryn, Ozbay, A. Burak , Limburg, Paul J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S146-S147

10.14309/01.ajg.0000703248.44831.07 Get It

S0299 Colorectal Cancer Screening by Test Type Prior to and Following Mt-sDNA Market Entry Among Average Risk Patients: A Real World Analysis
Fisher, Deborah A. , Miller‐Wilson, Lesley‐Ann , Wilson, Kathleen , Fendrick, Mark, Princic, Nicole , Limburg, Paul J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S146-S146

10.14309/01.ajg.0000703244.70853.a2 Get It